Exciting Updates on Lisata Therapeutics ASCEND Trial Results
Lisata Therapeutics, Inc. (Nasdaq: LSTA) has announced preliminary Cohort A results from its Phase 2 ASCEND trial, which investigates the efficacy of certepetide when combined with standard chemotherapy in treating metastatic pancreatic ductal adenocarcinoma (mPDAC). This trial, which is being conducted across multiple sites in Australia and New Zealand and is led by the Australasian Gastro-Intestinal Trials Group (AGITG), is showing promising data that could impact treatment options for patients.
Presentation of Preliminary Data
The initial findings from Cohort A of the ASCEND trial will be showcased in a poster session at an upcoming significant oncology symposium. Attendees will gain insights into the positive trends observed in overall survival rates among patients treated with certepetide in comparison to those who received a placebo.
Important Findings from Cohort A
Preliminary results indicate that the treatment group receiving certepetide exhibited a median overall survival (mOS) of 12.68 months, markedly higher than the 9.72 months observed in the placebo group. Notably, the treatment group saw four complete responses, whereas no patients in the placebo group demonstrated a complete response. This data not only underscores certepetide's potential but also highlights the need for continued research.
Future Expectations from Cohort B
Cohort B of the trial is anticipated to yield additional data in the near future. As researchers continue to assess the effects of different dosing regimens of certepetide, they expect even more favorable outcomes. This reinforces the company's strategy to advance certepetide’s development into Phase 3 trials in the near future.
Understanding Certepetide's Mechanism
Certepetide is an investigational cyclic peptide designed to enhance the effectiveness of standard chemotherapy. It works by facilitating a novel pathway that allows anti-cancer drugs to reach tumors more effectively. By modifying the tumor microenvironment, certepetide may significantly improve the response of tumors to immunotherapy treatments, showcasing its dual potential.
Lisata Therapeutics' Vision and Strategy
Lisata Therapeutics aims to develop and commercialize innovative therapies that address critical medical needs, particularly in treating advanced solid tumors. The company’s extensive research into certepetide's efficacy continues to pave the way for pioneering treatment methods. With notable designations for its drug candidate from regulatory bodies, Lisata is positioning itself for future advancements in its clinical development pipeline.
Frequently Asked Questions
What is the ASCEND trial?
The ASCEND trial is a Phase 2 study evaluating the efficacy of certepetide in combination with standard chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma.
What were the key findings from Cohort A of the trial?
Cohort A results showed a median overall survival of 12.68 months for patients treated with certepetide compared to 9.72 months for those receiving placebo.
What is certepetide?
Certepetide is an investigational drug candidate that enhances the delivery of anti-cancer therapies to solid tumors through a unique mechanism of action.
When will results from Cohort B be available?
Results from Cohort B are expected to be released in the coming months, further contributing to the understanding of certepetide's efficacy.
How is Lisata Therapeutics positioned in the market?
Lisata Therapeutics is focused on developing innovative therapies and has secured various designations for certepetide, demonstrating its potential in treating solid tumors.
